Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2018-10-10 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Dosing Begins in First Clinical Trial of MCY-M11
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's Regulatory News Service (RNS). It announces a specific corporate milestone: the commencement of dosing in a Phase I clinical trial for the company's lead therapeutic candidate. It does not contain financial statements, annual reports, or governance disclosures, but rather serves as a regulatory announcement of operational progress. As it does not fit into more specific categories like M&A or dividend notices, it is classified as a general regulatory filing.
2018-10-10 English
Dosing Begins in First Clinical Trial of MCY-M11
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) regarding the commencement of a clinical trial for a new therapeutic candidate. It does not contain financial statements, annual reports, or governance disclosures, but rather serves as a corporate announcement of operational progress. As it is a general regulatory announcement that does not fit into more specific categories like M&A or dividend notices, it is classified as a Regulatory Filing (RNS).
2018-10-10 English
Notice of AGM
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. regarding the distribution of formal notice, resolutions, and proxy materials for an upcoming Annual General Meeting (AGM). It explicitly states that these documents have been circulated to shareholders and are available on the company's website. Following the 'Menu vs Meal' rule, this is an announcement of the availability of meeting materials rather than the meeting materials themselves, making it a Report Publication Announcement (RPA).
2018-10-08 English
Notice of AGM
AGM Information Classification · 98% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. regarding the distribution of formal notice, resolutions, and proxy materials for an upcoming Annual General Meeting (AGM). It explicitly states that these documents have been circulated to shareholders and are available on the company's website. Per the 'Menu vs Meal' rule, this is an announcement of the availability of meeting materials rather than the meeting materials themselves, making it a Report Publication Announcement (RPA).
2018-10-08 English
Results for the Half Year ended 30 June 2018
Interim / Quarterly Report Classification · 95% confidence The document is an announcement of financial results for the six months ended 30 June 2018. It contains detailed financial highlights, operational updates, a management review, and a financial review. While it is titled 'Results for the Six Months', it is presented as an RNS (Regulatory News Service) announcement, which is the standard format for interim financial reporting in the UK/LSE market. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-09-24 English
Results for the Half Year ended 30 June 2018
Interim / Quarterly Report Classification · 95% confidence The document is an announcement of financial results for the six months ended 30 June 2018. It contains detailed financial highlights, operational updates, a management review, and a financial review. While it is titled 'Results for the Six Months', it is presented as an RNS (Regulatory News Service) announcement, which is the standard format for interim financial reporting in the UK/LSE market. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-09-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.